Ivosidenib is an oral small molecule inhibitor of mutated IDH1 approved by the FDA for the treatment of adult patients with relapsed or refractory AML with a susceptible IDH1 mutation. This evidence concerns the gene IDH1 and acute myeloid leukemia.